NCT01072266View on ClinicalTrials.gov

A Dose-escalation Study in Subjects With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

January 31, 2013

Conditions
Solid TumorAdvanced CancerMetastatic Cancer
Interventions
DRUG

INCB028060

10 mg and 50 mg capsules will be provided and dosed per the dosing schedule.

Trial Locations (2)

Unknown

Baltimore

Nashville

Sponsors

Lead Sponsor

Incyte Corporation

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Incyte Corporation

INDUSTRY